Researchers include Benjamin M. Looney, Ph.D., Chang Qing Xia, M.D., Ph.D., Patrick Concannon, Ph.D., David Ostrov, Ph.D. and Michael J. Clare-Salzler, M.D.
UFDI investigators Jing Chen, M.D., Ph.D. and Clayton Mathews, Ph.D. contributed to the publication in BMC Biochemistry.
Dysfunction of vascular endothelial cells underlies the development and progression of several potentially life-threatening diseases, including diabetes.
Dr. Clare-Salzler and other researchers found that omega-3 FAs may protect against the development of RA-related autoimmunity in pre-clinical RA.
UFDI affiliate researcher Mark S. Segal, M.D., Ph.D. was the principle investigator of the study conducted.
Two recent publications explored different methods of delivering a vaccine for type 1 diabetes, both of which prevented 40 percent of mice from developing the disease.
UFDI faculty and a University of Miami researcher found that “reduced pancreas weight allows for comparisons across a wide range of donor ages by eliminating confounding variables.”…
UFDI researcher Dr. Benjamin Keselowsky’s paper ‘Biomaterials-Based Immunomodulation of Dendritic Cells’ was featured in Laura Santambrogio, M.D., Ph.D.’s latest book, Biomaterials in Regenerative Medicine and the Immune System. You can find Dr. Santambrogio’s book here.
Dr. Campbell-Thompson’s newly released publication showcases evidence that type 1 diabetes is a combined endocrine-exocrine disease in which the loss of functional beta cell mass is clinically apparent.
After isolating and expanding T cells, Dr. Brusko’s lab partnered with biomaterial engineers to create a nanoparticle vaccine to reinvigorate the T cells. Dr. Brusko is highly optimistic.
